These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Insulin-like growth factor I and growth hormone (GH) treatment in GH-deficient humans: differential effects on protein, glucose, lipid, and calcium metabolism. Mauras N; O'Brien KO; Welch S; Rini A; Helgeson K; Vieira NE; Yergey AL J Clin Endocrinol Metab; 2000 Apr; 85(4):1686-94. PubMed ID: 10770216 [TBL] [Abstract][Full Text] [Related]
24. Characterization of growth hormone enhanced donor site healing in patients with large cutaneous burns. Herndon DN; Hawkins HK; Nguyen TT; Pierre E; Cox R; Barrow RE Ann Surg; 1995 Jun; 221(6):649-56; discussion 656-9. PubMed ID: 7794069 [TBL] [Abstract][Full Text] [Related]
25. Regulation of the somatotropic axis by intensive insulin therapy during protracted critical illness. Mesotten D; Wouters PJ; Peeters RP; Hardman KV; Holly JM; Baxter RC; Van den Berghe G J Clin Endocrinol Metab; 2004 Jul; 89(7):3105-13. PubMed ID: 15240578 [TBL] [Abstract][Full Text] [Related]
26. Leptin levels in protracted critical illness: effects of growth hormone-secretagogues and thyrotropin-releasing hormone. Van den Berghe G; Wouters P; Carlsson L; Baxter RC; Bouillon R; Bowers CY J Clin Endocrinol Metab; 1998 Sep; 83(9):3062-70. PubMed ID: 9745404 [TBL] [Abstract][Full Text] [Related]
27. Endocrine and metabolic effects of growth hormone (GH) compared with GH-releasing peptide, thyrotropin-releasing hormone, and insulin infusion in a rabbit model of prolonged critical illness. Weekers F; Michalaki M; Coopmans W; Van Herck E; Veldhuis JD; Darras VM; Van den Berghe G Endocrinology; 2004 Jan; 145(1):205-13. PubMed ID: 14551231 [TBL] [Abstract][Full Text] [Related]
28. Anabolic and anticatabolic agents used in burn care: What is known and what is yet to be learned. Gus EI; Shahrokhi S; Jeschke MG Burns; 2020 Feb; 46(1):19-32. PubMed ID: 31852612 [TBL] [Abstract][Full Text] [Related]
29. Integrated nutritional, hormonal, and metabolic effects of recombinant human growth hormone (rhGH) supplementation in trauma patients. Jeevanandam M; Holaday NJ; Petersen SR Nutrition; 1996; 12(11-12):777-87. PubMed ID: 8974104 [TBL] [Abstract][Full Text] [Related]
30. The somatotropic axis in critical illness: effect of continuous growth hormone (GH)-releasing hormone and GH-releasing peptide-2 infusion. Van den Berghe G; de Zegher F; Veldhuis JD; Wouters P; Awouters M; Verbruggen W; Schetz M; Verwaest C; Lauwers P; Bouillon R; Bowers CY J Clin Endocrinol Metab; 1997 Feb; 82(2):590-9. PubMed ID: 9024260 [TBL] [Abstract][Full Text] [Related]
31. Growth factors in critical illness: regulation and therapeutic aspects. Frost RA; Lang CH Curr Opin Clin Nutr Metab Care; 1998 Mar; 1(2):195-204. PubMed ID: 10565348 [TBL] [Abstract][Full Text] [Related]
32. Growth hormone secretagogues in critical illness. Van den Berghe G Horm Res; 1999; 51 Suppl 3():21-8. PubMed ID: 10592440 [TBL] [Abstract][Full Text] [Related]
33. [Systematic evaluation on effectiveness and safety of recombinant human growth hormone in treating adult patients with severe burn]. Tian FY; Wu B; Xu T; Jiang XH Zhonghua Shao Shang Za Zhi; 2017 Sep; 33(9):568-573. PubMed ID: 28926879 [No Abstract] [Full Text] [Related]
34. Growth hormone and insulin-like growth factors in critical illness. Gibson FA; Hinds CJ Intensive Care Med; 1997 Apr; 23(4):369-78. PubMed ID: 9142574 [No Abstract] [Full Text] [Related]
35. Effect of intensive insulin therapy on the somatotropic axis of critically ill children. Gielen M; Mesotten D; Brugts M; Coopmans W; Van Herck E; Vanhorebeek I; Baxter R; Lamberts S; Janssen JA; Van den Berghe G J Clin Endocrinol Metab; 2011 Aug; 96(8):2558-66. PubMed ID: 21632816 [TBL] [Abstract][Full Text] [Related]
36. GH and IGF-I as therapeutic agents for osteoporosis. Agnusdei D; Gentilella R J Endocrinol Invest; 2005; 28(8 Suppl):32-6. PubMed ID: 16323827 [TBL] [Abstract][Full Text] [Related]
37. Ageing, growth hormone and physical performance. Lanfranco F; Gianotti L; Giordano R; Pellegrino M; Maccario M; Arvat E J Endocrinol Invest; 2003 Sep; 26(9):861-72. PubMed ID: 14964439 [TBL] [Abstract][Full Text] [Related]
38. GH, IGF-I and binding proteins in altered nutritional states. Ross RJ Int J Obes Relat Metab Disord; 2000 Jun; 24 Suppl 2():S92-5. PubMed ID: 10997619 [TBL] [Abstract][Full Text] [Related]
39. Administration of growth hormone and nandrolone decanoate alters mRNA expression of the GABAB receptor subunits as well as of the GH receptor, IGF-1, and IGF-2 in rat brain. Grönbladh A; Johansson J; Nyberg F; Hallberg M Growth Horm IGF Res; 2014; 24(2-3):60-6. PubMed ID: 24480470 [TBL] [Abstract][Full Text] [Related]
40. Burns: where are we standing with propranolol, oxandrolone, recombinant human growth hormone, and the new incretin analogs? Gauglitz GG; Williams FN; Herndon DN; Jeschke MG Curr Opin Clin Nutr Metab Care; 2011 Mar; 14(2):176-81. PubMed ID: 21157309 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]